银轮股份(002126) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥1,274,726,672.29, a decrease of 8.20% compared to ¥1,388,604,575.34 in the same period last year[9]. - Net profit attributable to shareholders was ¥93,052,233.55, down 14.56% from ¥108,914,529.07 year-on-year[9]. - Basic earnings per share decreased by 14.29% to ¥0.12 from ¥0.14 in the same period last year[9]. - Net profit for the current period was ¥100,703,848.27, down 12.3% from ¥114,895,034.28 in the previous period[61]. - The company reported a basic earnings per share of ¥0.13, up from ¥0.12 in the previous period[67]. - Total operating revenue for the current period was ¥1,274,726,672.29, a decrease of 8.2% compared to ¥1,388,604,575.34 in the previous period[54]. - Operating profit for the current period is ¥112,656,537.32, slightly down from ¥115,903,579.71 in the previous period[64]. - The total comprehensive income for the current period is ¥99,336,011.78, compared to ¥98,267,978.15 in the previous period[66]. Cash Flow - The net cash flow from operating activities was -¥92,851,643.90, representing a significant decline of 1,595.76% compared to -¥5,475,532.39 in the previous year[9]. - Cash flow from operating activities generated a net outflow of ¥92,851,643.90, compared to a smaller outflow of ¥5,475,532.39 in the previous period[68]. - Operating cash flow net amount decreased to -75,332,430.57 CNY from 41,001,129.71 CNY year-on-year[75]. - Cash inflow from operating activities totaled 618,638,412.42 CNY, compared to 478,962,282.44 CNY in the previous period[75]. - Cash outflow from operating activities rose to 693,970,842.99 CNY from 437,961,152.73 CNY year-on-year[75]. - The net cash flow from financing activities increased by 46.23% year-on-year, mainly due to increased operational funding needs[21]. - Financing activities produced a net cash flow of 196,017,778.61 CNY, up from 168,688,343.74 CNY year-on-year[78]. Assets and Liabilities - Total assets at the end of the reporting period were ¥8,599,707,196.74, an increase of 2.08% from ¥8,424,106,635.59 at the end of the previous year[9]. - Current liabilities rose to ¥4,176,387,473.07, compared to ¥3,957,638,024.48, indicating an increase of about 5.53%[42]. - The total liabilities reached ¥4,415,842,326.97, up from ¥4,340,234,360.12, marking an increase of around 1.74%[42]. - The company's total owner's equity rose to ¥4,183,864,869.77 from ¥4,083,872,275.47, showing an increase of about 2.0%[45]. - Long-term borrowings decreased to ¥70,574,896.21 from ¥211,472,457.11, a significant reduction of about 66.7%[42]. Investments - Investment income increased by 288.54% year-on-year, primarily due to the sale of part of the shares of Shengda Bio[21]. - The company reported investment income of ¥35,244,070.53, significantly up from ¥9,070,784.43 in the previous period[57]. - The company has invested a total of RMB 47.93 million in entrusted wealth management products, with an outstanding balance of RMB 43.10 million[26]. Shareholder Information - The top shareholder, Tiantai Yinlun Industrial Development Co., Ltd., holds 10.16% of the shares, totaling 80,444,000 shares[14]. - The company did not engage in any repurchase transactions during the reporting period[18]. - The company repurchased a total of 7,191,039 shares, accounting for 0.9079% of the total share capital, with a total transaction amount of approximately RMB 53.05 million[22]. Expenses - Total operating costs decreased to ¥1,170,143,040.26 from ¥1,276,096,163.22, reflecting a reduction of 8.3%[57]. - Research and development expenses increased to ¥58,840,281.21 from ¥51,546,563.52, reflecting a growth of 14.1%[57]. - The company incurred financial expenses of ¥9,293,951.94, a decrease from ¥17,700,294.33 in the previous period[64]. - Financial expenses decreased by 40.99% year-on-year, mainly due to increased exchange gains[21].